Legend Biotech Corp (LEGN): what the price requires

At today's price, Legend Biotech Corp (LEGN) is priced for today's economics sustained for ~5.4 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-19 · Exported: 2026-07-20 · Source: https://boothcheck.com/report/LEGN

Headline

FieldValue
TickerLEGN
CompanyLegend Biotech Corp
Sector / IndustryHealthcare
Current price$22.28/sh

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basisrevenue-multiple
EV / sales paid8.7x
Steady-state operating margin assumed24.6%
Must persist for5.4y

Solve inputs: computed at a 8.3% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~2 years.

How unusual the bet is: within-range (limited comparison data)

ReferenceValue
sustained it ~5.4 years at this level35%
implied end-window share0%

Valuation X-Ray

Every valuation family lands below the price. The price therefore requires assumptions beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset8.68x2expensive
Earnings—0—
Relative2.00x2expensive
Growth1.43x2expensive

Families that call it expensive: Asset, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.2%); the inversion above states its own rate.

Per-Model Detail (n=6)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$0.00—noNegative/zero FCF — equity value floored at $0
DCF Exit MultipleGrowth$0.00—noNegative/zero FCF or EBITDA — equity value floored at $0
Relative ValuationRelative$11.152.00xyesP/S fallback (negative EPS): Sector P/S 4.0x × TTM revenue — excluded from consensus
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$2.718.22xyesBook value floor: BV/sh $2.71, ROE negative
Two-Stage Excess ReturnAsset$2.449.13xyesBook value with convergence: BV/sh $2.71, ROE converges to ke
Discounted Future Market CapGrowth$32.330.69xyesRev $1.0B, growth 30% (input: historical growth; tapered), Terminal P/S: 6.4x / 8.0x / 9.6x (bear / base = today's held flat / bull, cap 12x)
Peter Lynch Fair ValueRelative$0.00—noNegative/zero EPS — earnings-based value floored at $0
Margin TrajectoryGrowth$10.242.18xyesMargin ramp: -29% → 12% over 7yr, rev growth 30% (input: historical growth; tapered)
Earnings Power ValueEarnings——no—
Residual IncomeAsset——no—
Graham NumberAsset——no—
EV/EBITDA RelativeRelative——no—
FCF YieldEarnings——no—
SBC-Adj FCF YieldEarnings——no—
Ben Graham FormulaEarnings——no—
ROIC-Justified P/BAsset——no—
P/Sales SectorRelative$11.152.00xyesRevenue $1.03B × sector P/S 4.0x
PEG Fair ValueRelative——no—
Earnings YieldEarnings——no—
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Net cash$582.8m
Share count CAGR (dilution)4.5%
Burning cashyes

Operating profit is negative or near zero and the company has no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so years-to-repay cannot be computed honestly.

Operating profit is negative or near zero and there is no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so interest coverage cannot be computed honestly.

Bullet Takeaways

Bull Case

Here is the counterintuitive part. Legend Biotech still posts losses, and the reflex with a loss-making biotech is to assume the market has priced a fantasy. It has not, at least not an extreme one. At $22.28 (July 19, 2026) the price is set against sales rather than profits, at about 8.7x revenue, and what that embeds is modest for the genre: today's trajectory sustained for roughly 5.6 years and an eventual operating margin near 24.6%. The analysis rates that within range rather than a stretch. For a cell therapy growing the way this one is, a runway of the current pace lasting under six years is not a heroic assumption.

The engine of that growth is CARVYKTI, the BCMA-directed CAR-T therapy Legend developed with Johnson & Johnson's Janssen unit for multiple myeloma. Net trade sales reached about $597 million in the first quarter, up 62% on the year, with international sales up 222% as the therapy reached 18 markets and more than 300 treatment sites. Legend books its share as collaboration revenue, $298.4 million in the quarter, and the gross margin on that stream runs above 61%. Commercial-stage peers describe the same scaling dynamic in their own filings; Alnylam, for one, frames a lead therapy's potential to significantly improve our gross margins on product sales and our non-GAAP operating income margin [ALNY FY2025 10-K]. The J&J partnership matters in both directions: the partner funds and shares the commercial build, which is why a company this early is already talking about profitability.

The balance sheet backs the story. Legend held about $835 million in cash and deposits at the end of the first quarter with no long-term debt, roughly $582.8M net of other borrowings, and an April milestone of $55 million from the Janssen collaboration added to it. Losses are narrowing fast, from $101 million a year earlier to $54.3 million in the quarter. A biotech that reaches self-funding before its cash runs low removes the dilution overhang that sinks so many single-product stories, even though the share count has still grown about 4.5% a year to get here.

Bear Case

The bear case starts with which stage of the story the market is buying. CARVYKTI is in the steep part of a launch, with international sales up 222% in a single quarter, and a launch at that slope is the easiest thing in biotech to mistake for a durable franchise. Early-line expansion and new geographies throw off a burst of growth that eventually meets a ceiling: the size of the treatable population, the number of certified cell-therapy centers, and the patients who can wait weeks for a bespoke product to be manufactured for them one at a time. Paying about 8.7x sales prices the ramp as if that ceiling sits far away. One reading of the recent manufacturing expansion is capacity built ahead of durable demand rather than in response to it.

Competition is the second pressure, and it is specific. Multiple myeloma has become the most crowded cell-therapy and bispecific battleground in oncology. Off-the-shelf bispecific antibodies hit the same BCMA target with no manufacturing wait, and a rival CAR-T competes directly for the same treatment slots. Legend's defense is efficacy and earlier-line positioning, but the whole company rides essentially one asset, so a single competitive or safety setback lands on nearly all of the revenue. The peer set is candid about exactly this in its filings: Acadia warns that competitors may succeed in developing technologies or drugs that are more effective, safer, more affordable, or more easily administered than ours [ACAD FY2025 10-K], which is the off-the-shelf argument against a manufactured therapy stated in a rival's own words.

Then the numbers. The price asks for an eventual operating margin near 24.6% held while revenue grows near its self-funding ceiling for about 5.6 years. That is not an outrageous bet, and the analysis says as much, but it is still a bet on a company that has not yet earned an operating profit: the trailing operating line is a loss of about $136.5 million, and coverage of interest cannot be computed honestly on a negative operating result. The fair frame for a single-product commercial biotech is that cash-flow math undervalues a working therapy and overstates certainty about its future at once. If CARVYKTI's growth fades before that margin arrives, the multiple compresses toward the level the sales alone support, well beneath today's quote by the peer-multiple reading.

Valuation

At $22.28 (July 19, 2026), Legend cannot be valued on profits it does not yet make, so the price is set against sales, at about 8.7x revenue. Inverted, that multiple embeds a specific bet: revenue growing near its self-funding ceiling for roughly 5.6 years, resolving into an eventual operating margin near 24.6%. Unusually for a loss-making biotech, the analysis rates that assumption within range rather than stretched, though on limited comparison data, and Legend's recent trajectory has run faster still.

Set against the standard methods, every family lands below today's price, and the pattern is the useful part. The forward-growth methods come closest, leaving the price at about 1.4x their central estimate, which fits a company whose entire case is forward growth. The peer-multiple methods sit well below the quote, and the asset-value methods, anchored on book value, land far beneath it, as they do for any biotech whose worth is in a marketed therapy rather than on the balance sheet. That spread is not a signal the stock is broken; it is the signature of a growth-stage biotech, where the value lives in a franchise the static methods cannot frame.

Solvency is the part that lets the bet play out. Legend holds $582.8M in net cash, and while it still spends more than it earns, management has guided to adjusted profitability this year, which would end the cash drain before the balance sheet is tested. The exposure that matters is not insolvency; it is whether one therapy can carry the growth assumption the price already holds across the next 5.6 years.

Catalysts

The near-term driver is the quarterly CARVYKTI sales print. First-quarter net trade sales of about $597 million grew 62% on the year, and management reaffirmed guidance for company-wide adjusted profitability in 2026. The next report is the checkpoint on whether the international ramp and earlier-line expansion keep the growth curve steep or begin to flatten. An April milestone payment of $55 million from the Janssen collaboration is the kind of non-dilutive inflow that recurs as the therapy hits development and sales targets.

Analyst sentiment is firmly bullish and sits well above the current quote. The consensus price target is about $60.65, with a cluster of strong-buy ratings, and a recent initiation landed at $50. That distance between the market quote and the street's targets is worth reading with some skepticism: it prices near-flawless execution of a single-product launch, which is precisely the assumption the competitive field is built to attack.

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Legend Biotech Q1 2026 results, May 2026 · Legend Biotech disclosure, April 2026 · analyst estimates, July 2026

View the full interactive LEGN report on boothcheck